1. Dissemination
  2. Presentations

Presentations

An overview of the oral presentations:

  • C.Talbot, D.Azria, T.Burr, J. Chang-Claude, A. Dunning, C. Herskind, D. De Ruysscher, R. Elliott, S. Gutiérrez-Enríquez, P.Lambin, A. Müller, T. Rancati, B. Rosenstein, T. Rattay, P. Seibold, L. Veldeman, A. Vega, F. Wenz, R.Valdagni, A. Webb, C. West, The REQUITE project: integrating biomarkers and clinical predictors of radiotherapy side effects, ESTRO37: symposium Radiogenomics, Barcelona, Spain, April 20-24, 2018. Radiotherapy and Oncology, Volume 127, Supplement 1, April 2018, Pages248-s249  Abstract

 

  • C.West, REQUITE Big Data Resource for Validating Predictive Models and Biomarkers of Radiotherapy Toxicity. ESTRO37: proffered papers, session about Biomarkers, Barcelona, Spain, April 20-24, 2018. Radiotherapy and Oncology, Volume 127, Supplement 1, April 2018, Page s78:  Abstract

 

  • C. West, The implementation of PROM in research and clinical practice in different cancer sites in the REQUITE study (radiogenomics).ESTRO 36 : Clinical pre-meeting course: "patient reported outcome measures (PROMS) in radiotherapy research and clinical practice" ,  Vienna, Austria, May 5-9, 2017. Abstract

 

  • Nuradh Joseph, Tiziana Rancati, Alessandro Cicchetti, Riccardo Valdagni, Jenny Chang-Claude, Susan Davidson, Kerstie Johnson, Chris Talbot, Adam Webb, Alan McWilliam, Catharine West, Ananya Choudhury: A higher whole pelvic integral dose is associated with worsening fatigue and functional outcome in prostate cancer patients treated with intensity modulated radiotherapy. 2016 NCRI Cancer Conference, Liverpool, United Kingdom, November 6-9, 2016 Abstract

 

  • D. Azria, How to personalize radiotherapy. Annual Congress of the General Network in Oncology, Montpellier (France), September 27, 2016.

 

 

  • Jenny Chang-Claude, Petra Seibold, Akke Botma, Irmgard Helmbold, Sabine Behrens, Ana Vega, R. Paul Symonds, Riccardo Valdagni, David Azria, Frederik Wenz, Dirk De Ruysscher, Anaya Choudhury, Barry S. Rosenstein, Renee Bultijnck, Philippe Lambin, Chris J. Talbot, Catharine West, Tiziana Rancati: Acute adverse effects and related quality of life in prostate cancer patients treated with radiotherapy in the multicentre REQUITE cohort study. HEC 2016, Munnich, Germany, September 1, 2016. Abstract

 

  • D. Azria, How to predict late effects after radiotherapy. Annual Congress of Medical Oncologist, Paris (France), June 30, 2016.

 

  • C. Talbot, A. Appanvel, A. Botma, T. Rancati, A. Webb, D. Azria, T. Burr, J. Chang-Claude, C. Herskind, D. De Ruysscher, R. Elliott, S. Gutiérrez Enríquez, P. Lambin, B. Ronstein, T. Rattay, H. Thierens, A. Vega, F. Wenz, R. Valdagani, C. West, REQUITE: Validation of Radiation Induced Lymphocyte Apoptosis assay (RILA) as a predictor for radiotherapy induced side effects. Association of Radiation Research (ARR), Leicester (United Kingdom), June 27-29, 2016.

 

 

  • D. Azria, Personalized radiotherapy. National Congress of Genomic Medicine, Montpellier (France), June 17, 2016.

 

 

 

  • Tim Rattay, Kerstie Johnson, Samuel Lavers, David Azria, Akke Botma, Jenny Chang-Claude, Susan Davidson, Dirk De Ruysscher, Sara Gutiérrez Enrí quez, Phillipe Lambin, Tiziana Rancati, Barry Rosenstein, Christopher Talbot, Hubert Thierens, Ricardo Valdagni, Ana Vega, Adam Webb, Frederik Wenz, Catharine West, Tom Burr, Alison Dunning, R. Paul Symonds. The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients. Association Of Breast Surgery Conference & AGM , Manchester (United Kingdom), May 16-17, 2016. abstract published in The European Journal of Surgical Oncology - EJSO - Vol. 42, Issue 5 May 2016, S5

 

 

 

 

 

  • B.S. Rosenstein, Using genetic/genomic information to enhance precision medicine and improve clinical outcomes for cancer patients treated with radiotherapy. American Association of Cancer Research (AACR), New Orleans (USA), April 19, 2016.

 

 

  • D. Azria, Lymphocytes as predictor of late effects. French Speaker Congress in Urology Cancer, Lyon (France), March 18, 2016.

 

  • D. Azria, How to predict late effects after radiotherapy. Young Radiation Oncologist Society, Paris (France), March 9, 2016.

 

  • G. Defraene, W. van Elmpt, D. De Ruysscher, Baseline CT image and isodose shape features improve prognostic models for dyspnea after RT in NSCLC. Belgian Hospital Physicist Association (BHPA) 2016, Liège (Belgium), February 26-27, 2016.

 

 

 

  • B.S. Rosenstein, How will big data improve clinical and basic research in radiation therapy AND The potential of big data resources for radiogenomics and pathologic/genetic data. American Society for Radiation Oncology (ASTRO), San Antonio (USA), October 18-21, 2015.

 

  • D. Azria, How to predict radiation induced late effects. Annual Congress of the French Oncologist Society, Paris (France), October 10, 2015.

 

 

  • D. Azria, Lymphocytes and late effects. Annual Congress of Urologist, Paris (France), June 26, 2015.

 

 

  • D. Azria, How to predict radiation induced late effects. Annual Congress of Radiation Oncologist of the South of France, Nice (France), June 19, 2015.

 

 

  • D. Azria, How to predict radiation induced late effects. Spanish Annual Congress, Valencia (Spain), June 4, 2015.

 

  • P. Peleterio, Proyecto REQUITE. X Reunión del Grupo Gallego de Oncología Radioterápica del Norte, Zaragoza (Spain), May 8, 2015.

 

 

  • G. Defraene, W. van Elmpt, W. Crijns, P. Slagmolen, D. de Ruysscher. CT characteristics allow to identify individual and regional susceptibility for radiation-induced lung damage. The 3rd ESTRO forum (European SocieTy for Radiotherapy and Oncology), Barcelona (Spain), April 24-28, 2015. Abstract number: OC- 0253, Page 149.

 

  • C.Talbot, D. Azria, A.J.Brookes, T.Burr, J. Chang-Claude, S. Davidson, D. De Ruysscher, A.M. Dunning, R. Elliott, S. Gutiérrez Enríquez, P. Lambin, T. Rancati, B. Rosenstein, P. Seibold, R. P. Symonds, H. Thierens, R. Valdagni, A.Vega, F. Wenz, M. Yuille and C.M. West. Validating predictive models and biomarkers of radiotherapy toxicity: the REQUITE project. Symposium with Proffered Papers: Biomarkers of normal tissue toxicity at the 3rd ESTRO forum (European SocieTy for Radiotherapy and Oncology), Barcelona (Spain), April 24-28, 2015. Abstract number: SP- 0169, Page 104.

 

  • C. Mbah, O. Thas, J. De Neve, H. Thierens, J. Chang-Claude, P. Seibold, I. Helmbold, S. Behrens, O. Popanda, P. Schmezer and K. De Ruyck. A demonstration of overfitting and model selection in unique setting of two independent data sets. The International Biometric Society (IBS) Channel Network Conference, Nijmegen (The Netherlands), April 20-22, 2015.

 

 

 

  • A. Gómez Caamaño, The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve quality of life in cancer survivors. I Reunión Científica en Oncología Translacional, Madrid, Spain, January 30, 2015.

 

  • C.M.L. West, The importance of considering patient at risk of developing late side-effects after curative intent radiotherapy. Workshop Radiobiology applied to oncology, Montpellier, France, November 14, 2014

 

  • D. Azria, REQUITE European Project Presentation. Société Française de Radiothérapie Oncologique (SFRO), Paris La Défense, France, October 16, 2014

 

  • G. Defraene, D.De Ruysscher, Imaging-based dose redistribution in the normal lung. 6th Annual Radiogenomics Consortium (RGC) Meeting, Heidelberg, Germany, October 13, 2014.

 

  • G. Defraene, D.De Ruysscher, Imaging-based dose redistribution in the normal lung. LPRL Meeting (Landelijk Platform voor Radiotherapie bij Longtumoren), Utrecht, The Netherlands, October 9, 2014.

 

 

 

  • C.Talbot, D.Azria, A. Brookes, T. Burr, J. Chang-Claude, S. Davidson, D. De Ruysscher, A. Dunning, R. Elliott, S. Gutiérrez Enríquez, P. Lambin, L. Lozza, Ti. Rancati, B. Rosenstein, R. P. Symonds, H. Thierens, R. Valdagni, A.Vega, F. Wenz, M. Yuille and C. West. The REQUITE project: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve quality of life in cancer survivors. Annual Meeting of UK’s Association of Radiation Research in Sussex (UK), June 29 – July 2, 2014.

 

 

  • Fachal, Dorling, Kerns, RGC Prostate GWAS meta-analysis, International Radiogenomics Consortium (RGC) meeting, Vienna, Austria, April 4, 2014.

 

  • Dunning, Oncoarray update, International Radiogenomics Consortium (RGC) meeting, Vienna, Austria, April 4, 2014.

 

  • Dorling & Ahmed, Prostate risk SNPs and risk of radiotherapy toxicity. International Radiogenomics Consortium (RGC) meeting, Vienna, Austria, April 4, 2014.

 

  • A. Vega, Radiogenomics: Looking for genetic susceptibility to radiation, Investigación Biomédica del Cáncer en Galicia, A Coruña, Spain, March 13, 2014.

 

  • T. Rancati, C Talbot, D. Azria, A. Brookes, T. Burr, J. Chang-Claude, S. Davidson, D. De Ruysscher, A. Dunning, R. Elliott, S. Gutiérrez Enríquez, P. Lambin, L. Lozza, B. Rosenstein, R.P. Symonds, H. Thierens, R. Valdagni, A. Vega, F. Wenz, M. Yuille and C. West. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects. The International Conference on Translational Research in Radio-Oncology and Physics for Health in Europe in Geneva (Switzerland), February 10-14, 2014. Abstract number 163, S80, Page 98/129.